Tag - BriaCell Therapeutics

Developments

BriaCell doses first patient in advanced breast cancer combination study

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF)initiated dosing in a Phase 1/2a clinical study of its lead product candidate, Bria-IMT, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced...

October 7, 2019

Executive Moves

BriaCell Therapeutics names Richard Berman to board

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed Richard Berman to its board of directors. Mr. Berman has more than 35 years of experience in venture capital; senior management; and mergers and acquisitions. He...

August 13, 2019

Tag - BriaCell Therapeutics

BriaCell doses first patient in advanced breast cancer combination study

BriaCell Therapeutics names Richard Berman to board

General

More